Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Other Operating Expenses (2021 - 2024)

Relay Therapeutics (RLAY) has disclosed Other Operating Expenses for 4 consecutive years, with -$11.4 million as the latest value for Q2 2024.

  • On a quarterly basis, Other Operating Expenses fell 428.53% to -$11.4 million in Q2 2024 year-over-year; TTM through Mar 2025 was -$11.4 million, a 56.86% decrease, with the full-year FY2024 number at -$13.2 million, down 105.64% from a year prior.
  • Other Operating Expenses was -$11.4 million for Q2 2024 at Relay Therapeutics, down from -$1.8 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $134.9 million in Q2 2021 to a low of -$11.4 million in Q2 2024.
  • A 4-year average of $8.2 million and a median of -$1.2 million in 2023 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: crashed 1361.24% in 2022, then skyrocketed 80.4% in 2023.
  • Relay Therapeutics' Other Operating Expenses stood at $836000.0 in 2021, then plummeted by 1361.24% to -$10.5 million in 2022, then surged by 80.4% to -$2.1 million in 2023, then tumbled by 450.27% to -$11.4 million in 2024.
  • Per Business Quant, the three most recent readings for RLAY's Other Operating Expenses are -$11.4 million (Q2 2024), -$1.8 million (Q1 2024), and -$2.1 million (Q4 2023).